3SBio Revenue

In the year 2024, 3SBio had annual revenue of 9.11B CNY with 16.53% growth. 3SBio had revenue of 4.72B in the half year ending December 31, 2024, with 25.12% growth.

Revenue

9.11B CNY

Revenue Growth

+16.53%

P/S Ratio

7.69

Revenue / Employee

1.63M CNY

Employees

5,577

Market Cap

9.59B USD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	9.11B	1.29B	16.53%
Dec 31, 2023	7.82B	950.20M	13.84%
Dec 31, 2022	6.87B	483.73M	7.58%
Dec 31, 2021	6.38B	794.37M	14.22%
Dec 31, 2020	5.59B	269.55M	5.07%
Dec 31, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2018	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2017	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2016	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2015	Upgrade Pro	Upgrade Pro	Upgrade Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Endo, Inc.	1.73B
Veradigm	588.02M
Tian'an Technology Group	1.78M
Elite Pharmaceuticals	84.04M
Glass House Brands	215.62M
Northwest Biotherapeutics	1.47M
American Oncology Network	1.76B
Silence Therapeutics	27.70M

Revenue Rankings

3SBio News

5 days ago - Pfizer, Chinese biotech firm 3SBio complete licensing deal for cancer drug - South China Morning Post
2 months ago - Pfizer's Mega Deal Highlights China's Rising Role In Global Pharma - Benzinga
2 months ago - Pfizer Thinks Bigger With 3SBio Deal - Seeking Alpha
2 months ago - Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China - Investopedia
2 months ago - Pfizer strikes deal with China's 3SBio to license cancer drug - CNBC
2 months ago - Pfizer Secures Global Rights To China's 3SBio's Cancer Drug In $6 Billion Deal - Benzinga

More News